Sign Out
Special precautions for disposal and other handling: Prior to administration, 5.0 ml concentrate from one vial or the volume of the concentrate withdrawn as required must be immediately further diluted with 100 ml of calcium-free infusion solution (0.9% w/v sodium chloride solution or 5% w/v glucose solution).
Studies with glass bottles, as well as several containers types made from polyvinylchloride, polyethylene and polypropylene (prefilled with 0.9% w/v sodium chloride solution or 5% w/v glucose solution), showed no incompatibility with Zoledronic acid Fresenius Kabi.
Additional information on handling of Zoledronic acid Fresenius kabi, including guidance on preparation of reduced doses, is provided in section Recommended dose and Mode of administration.
Aseptic techniques must be followed during the preparation of the infusion. For single use only.
Only clear solution free from particles and discolouration should be used.
Healthcare professionals are advised not to dispose of unused Zoledronic acid Fresenius Kabi via the domestic sewage system.
Any unused medicinal product or waste material should be disposed in accordance with local requirements.
Incompatibilities: To avoid potential incompatibilities, Zoledronic acid concentrate is to be diluted with 0.9% w/v sodium chloride solution or 5% w/v glucose solution.
Zoledronic acid concentrate must not be mixed with calcium or other divalent cation-containing infusion solutions such as lactated Ringer's solution, and should be administered as a single intravenous solution in a separate infusion line.
